Hana Španielová

Hana Španielová


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2002 in Gene
Verified
Journal Article
Closed access
JKJarmila Králová
Jarmila Králová
TCThomas Czerny
Thomas Czerny
HŠHana Španielová
Hana Španielová
VRVeronika Ratajová
Veronika Ratajová
ZKZbynek Kozmik
Zbynek Kozmik

22 August 2019 in Materials
Verified
Journal Article
Open access
PDF file
JVJana Váňová
Jana Váňová
AHAlžběta Hejtmánková
Alžběta Hejtmánková
MKMarie Hubalek Kalbacova
Marie Hubalek Kalbacova
HŠHana Španielová
Hana Španielová
Viral particles (VPs) have evolved so as to efficiently enter target cells and to deliver their genetic material. The current state of knowledge allows us to use VPs in the field of biomedicine as nanoparticles that are safe, easy to manipulate, inherently biocompatible, biodegradable, and capable of transporting various cargoes into specific cells. Despite the fact that these virus-based nanoparticles constitute the most common vectors used in clinical practice, the need remains for further improvement in this area. The aim of this review is to discuss the potential for enhancing the efficiency and versatility of VPs via their functionalization with cell-penetrating peptides (CPPs), short peptides that are able to translocate across cellular membranes and to transport various substances with them. The review provides and describes various examples of and means of exploitation of CPPs in order to enhance the delivery of VPs into permissive cells and/or to allow them to enter a broad range of cell types. Moreover, it is possible that CPPs are capable of changing the immunogenic properties of VPs, which could lead to an improvement in their clinical application. The review also discusses strategies aimed at the modification of VPs by CPPs so as to create a useful cargo delivery tool.

1 February 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JNJitka Neburkova
Jitka Neburkova
FSFrantisek Sedlak
Frantisek Sedlak
JSJirina Zackova Suchanova
Jirina Zackova Suchanova
LKLibor Kostka
Libor Kostka
PSPavel Sacha
Pavel Sacha
PCPetr Cigler
Petr Cigler

24 April 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
JSJirina Zackova Suchanova
Jirina Zackova Suchanova
AHAlžběta Hejtmánková
Alžběta Hejtmánková
JNJitka Neburkova
Jitka Neburkova
PCPetr Cigler
Petr Cigler
JFJitka Forstova
Jitka Forstova
HŠHana Španielová
Hana Španielová

1 February 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JVJana Váňová
Jana Váňová
AHAlžběta Hejtmánková
Alžběta Hejtmánková
JSJiřina Žáčková Suchanová
Jiřina Žáčková Suchanová
PSPavla Sauerová
Pavla Sauerová
JFJitka Forstova
Jitka Forstova
HŠHana Španielová
Hana Španielová

7 February 2000 in FEBS Letters
Verified
Journal Article
Open access
PDF file
ZPZdena Palkova
Zdena Palkova
HŠHana Španielová
Hana Španielová
Vanesa GottifrediVanesa Gottifredi
Vanesa Gottifredi
DHDana Hollanderová
Dana Hollanderová
JFJitka Forstova
Jitka Forstova
PAPaolo Amati
Paolo Amati
Polyomavirus reaches the nucleus in a still encapsidated form, and the viral genome is readily found in association with the nuclear matrix. This association is thought to be essential for viral replication. In order to identify the protein(s) involved in the virus‐nuclear matrix interaction, we focused on the possible roles exerted by the multifunctional cellular nuclear matrix protein Yin Yang 1 (YY1) and by the viral major capsid protein VP1. In the present work we report on the in vivo association between YY1 and VP1. Using the yeast two‐hybrid system we demonstrate that the VP1 and YY1 proteins physically interact through the D‐E region of VP1 and the activation domain of YY1.